Merck Q4 2021 Earnings February 3, 2022 -- 1 of 38 -- Agenda 2 Strategy and Business Update Rob Davis President & Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 38 -- Forward-looking statement of Merck & Co., Inc., Kenilworth, N.J., USA 3 This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 38 -- Strategy & Business Update Rob Davis President & Chief Executive Officer -- 4 of 38 -- Delivered on our key strategic priorities in 2021 5 Achieved strong commercial and financial performance Advanced the pipeline to meet patient unmet need Executed on strategic business development to enhance pipeline Created long-term value for patients and shareholders -- 5 of 38 -- 2019 2020 2021 $41.5B +6% $48.7B +17% $39.1B* 2019 2020 2021 $4.53 +21% $6.02 +33% $3.73* Full Year Revenue Full Year EPS Exceptional Q4 and 2021 sales and earnings growth1 6 $13.5B +24% * Growth rate not available as restated 2018 results are not provided. 1. Results from continuing operations attributable to Merck & Co., Inc. Q4 Worldwide Sales $1.80 +84% Q4 Non-GAAP EPS -- 6 of 38 -- Expect continued strong growth in revenue and earnings 7 10% 15% 20% 25% 30% 35% 40% 45% 2019 2020 2021 2022 2025 $20 $25 $30 $35 $40 $45 $50 $55 $60 2019 2020 2021 2022 2025 … … Revenue Delivering visible de-risked revenue growth through 2025 Operating margins1 Commitment to drive leverage in the P&L with operating margins >43% by 2025 2021+ not to scale. 1. Non-GAAP operating margins $ in billions -- 7 of 38 -- Multiple levers to navigate the KEYTRUDA LOE 8 • Leverage leadership in oncology • Enhance durable growth drivers • Deploy cash flow from key assets to business development • Advance pipeline across key therapeutic areas Shorten period to return to strong growth Minimize the LOE gap Chart not to scale. Time Revenue -- 8 of 38 -- Business development remains an important strategic priority 9 $34.0B on business development transactions over the past 4 years $3.3B in 2018 $6.1B in 2019 $10.6B in 2020 $14.0B in 2021 Includes bolt-on acquisitions, strategic collaborations & licensing, and milestone payments • Accessing the best external science through value-enhancing business development • Financial flexibility to pursue both early- and late-stage opportunities • Unbounded by therapeutic area • Appropriately aggressive in adding innovative assets to help drive long-term revenue growth -- 9 of 38 -- ESG Priority Areas Made progress towards integrating ESG into our strategy 10 Access to health Employees Environmental sustainability Ethics & values • Inaugural issuance of $1 billion sustainability bond • Agreement with UNICEF to help ensure broad global access for molnupiravir • Hosting ESG Investor Event on February 23, 2022 -- 10 of 38 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 11 of 38 -- Merck achieved exceptional 2021 financial performance 1 12 WORLDWIDE SALES2 $48.7B+17% growth +16% ex-exchange NON-GAAP EPS3,4 $6.02+33% growth +32% ex-exchange Merck 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue; 3. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. 4. GAAP EPS of $1.51. -- 12 of 38 -- Strong Q4 sales growth across Human Health and Animal Health 13 Merck WORLDWIDE SALES1,2 $13.5B+ 24% growth +23% ex-exchange +14% ex-exchange, molnupiravir 3 $12.0B +23% growth +23% ex-exchange +13% ex-exchange, molnupiravir 3 Human Health $1.3B +8% growth +8% ex-exchange Animal Health 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. Excludes impact of foreign exchange and molnupiravir sales of $952M in the quarter -- 13 of 38 -- Oncology: KEYTRUDA drives continued momentum 14 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $4.6B increased 16% year-over-year, driven by momentum across key tumor types and recent launches – In the U.S., sales of $2.7B driven by growth across all key tumor types, including continued leadership in lung, as well as TNBC, RCC, HNSCC and MSI-H – Ex-U.S., 12% growth was driven by global uptake in lung as well as RCC and HNSCC • KEYTRUDA will continue to expand into earlier lines of therapy – Recent approvals in adjuvant RCC and Stage IIB or IIC melanoma, top-line results in NSCLC – In the U.S., more than half of KEYTRUDA’s annual growth will come from indications in earlier-stage treatment settings through 2025, and will represent roughly 30% of total U.S. KEYTRUDA 4Q19 4Q20 4Q21 $4.0B $3.1B $4.6B +27% +46% +16% -- 14 of 38 -- Oncology: Strong growth across broad portfolio • Lynparza sales increased 33%, with growth driven by advanced breast and continued uptake in other approved indications, including advanced prostate • Lenvima sales grew 31% driven by RCC and endometrial in the U.S. • WELIREG launching successfully in patients with certain VHL-associated tumors; potential to expand to broader RCC indications in the future Growth rates exclude the impact of foreign exchange. 4Q19 4Q20 4Q21 $206M $132M $268M 4Q19 4Q20 4Q21 $158M $124M $206M 15 +53% +>100% +33% +26% +73% +31% -- 15 of 38 -- Vaccines: GARDASIL benefitting from robust global demand and improved supply 16 • GARDASIL sales of $1.5B increased 50% year- over-year driven by strong global demand and increased supply – Ex-U.S., growth was driven by robust demand, increased supply and reallocation of doses – U.S. impacted by CDC purchase timing, stockpile replenishment in Q4 2020 and COVID-19 vaccine prioritization Increase/decrease in sales exclude the impact of foreign exchange. 4Q19 4Q20 4Q21 $998M $693M $1.5B +41% -16% +50% -- 16 of 38 -- Hospital: Strong performance by BRIDION and PREVYMIS 17 • BRIDION sales of $436M increased 24% year-over-year driven by increased usage of neuromuscular blockade reversal agents and BRIDION’s growing share within the class • Continued uptake of PREVYMIS, driven by ongoing launches • ZERBAXA supply reinitiated in Q4 following voluntary recall Growth rates exclude the impact of foreign exchange. 4Q19 4Q20 4Q21 $355M $313M $436M +13% +24% +24% -- 17 of 38 -- Animal Health: durable growth across portfolio 18 • Animal Health sales increased 8% to $1.3B, reflecting growth across geographies and species – Companion Animal sales increased 26%, driven by the BRAVECTO parasiticide line of products and vaccines – Livestock sales reflect higher demand globally for poultry and swine products o Sales were relatively flat compared with Q4 2020 due to an extra month of sales recorded in Q4 2020 related to the acquisition of Antelliq Growth rates exclude the impact of foreign exchange. 4Q19 4Q20 4Q21 $1.2B +6%$1.1B +10% $1.3B +8% -- 18 of 38 -- Q4 2021 continuing operations non-GAAP financial results summary: Delivered strong revenue and EPS growth Q4 2021 Q4 2020 Change Change Ex-FX Sales $13.5 $10.9 +24% +23% Non-GAAP Gross Margin1 74.8% 75.0% -0.2pts -0.8pts Operating Expenses $5.3 $5.2 +2% +3% Tax Rate 4.3% 15.3% -11.0pts N/A Non-GAAP EPS that excludes certain items 1 $1.80 $0.98 +84% +82% $ in billions, except EPS amounts 19 1. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. -- 19 of 38 -- Merck full-year 2022 guidance 1. GAAP Gross Margin Rate: ~68%. 2. GAAP Operating Expenses: Lower than 2021 by a low to mid-single-digit rate. 3. GAAP Tax Rate: ~12.0% - 13.0% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q4 2021 earnings release Guidance Key Assumptions Revenue $56.1B to $57.6B +15% to +18% (+17% to +20% ex-FX) • Assumes ~2% negative FX impact • Includes an expected $5-6 billion of molnupiravir revenue Non-GAAP Gross Margin Rate1 ~74.0% • Impacted by inclusion of molnupiravir profit share Non-GAAP Operating Expenses 2 Increase by mid-to-high single-digit rate • Includes a full year of R&D expenses as a result of the Acceleron acquisition; investments in portfolio and pipeline Other (Income) / Expense ~$350M of expense Tax Rate3 ~13.0-14.0% • Reflects impact of increased molnupiravir revenues and certain tax legislation changes for research and development expenses in 2022 Shares Outstanding ~2.53B GAAP EPS4 $5.76 to $5.91 Non-GAAP EPS4 $7.12 to $7.27 +18% to +21% (+19% to +22% ex-FX) • Assumes ~1% negative FX impact 20 -- 20 of 38 -- Molnupiravir can be an important treatment option to combat ongoing global pandemic 21 • Revenue guidance range of $5B to $6B in 2022, weighted to the first half of the year • Obtained 10 regulatory authorizations/approvals, including EUA from the FDA in December • Announced a number of supply and purchase agreements totaling ~10M courses of therapy; broad access strategy for low- and middle-income countries • Within the next few days, will have shipped >4M courses of therapy to >25 countries, including ~3M courses to the U.S. • Share global profits equally with partner Ridgeback Biotherapeutics -- 21 of 38 -- Key modeling assumptions & outlook 22 Oncology Pneumococcal GARDASIL Animal Health • Strong growth across oncology portfolio • Expect pneumococcal franchise to grow in 2022 • Uptake from recent launch of VAXNEUVANCE partially offset by PNEUMOVAX23 as the market shifts toward newer pneumococcal conjugate vaccines • Very strong growth driven by robust demand and increased supply in 2022, albeit not at the same pace as in 2021 • Global HPV vaccination levels remain low in eligible patient cohort • Sales to potentially double by 2030 • Above market growth in 2022 • Normalization of favorable companion animal trends -- 22 of 38 -- Higher Q4 business development spend driven by Acceleron acquisition 23 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase $ Billions 1 Capital allocation order of priority $2.6 $1.2 $1.6 $11.5 $0.0 2 1. Reflects Q4 spend 2. Includes payment for Acceleron acquisition -- 23 of 38 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 24 of 38 -- Driving value for patients and shareholders by progressing our pipeline in 2021 25 Oncology Key regulatory milestones Data and pipeline milestones • In the U.S. received 11 FDA approvals1, 1 NME (WELIREG). FDA accepted filing for KN-158 and granted priority review for OlympiA • In the EU, received 6 approvals2 and Q6W dosing regimen for KEYTRUDA. Received CHMP positive opinion for KN-361 and KN-5642 • In Japan, received 5 approvals • In China, received 3 approvals and Q6W dosing regimen for KEYTRUDA • In the U.S., received FDA approval for VAXNEUVANCE in the adult setting. FDA granted priority review for VAXNEUVANCE in the pediatric setting • In the EU, received CHMP positive opinion for VAXNEUVANCE in the adult setting • Received FDA Emergency Use Authorization for molnupiravir as well as authorization in other markets • In Japan, received approval for LYFNUA (gefapixant3) and RECARBRIO • Verquvo received approvals in the U.S., EU and Japan Infectious diseases, cardiometabolic & new products Vaccines • Presented new data and announced topline results for assets across our broad portfolio, including KN-091 and PROpel • Advanced novel mechanisms including coformulations with pembrolizumab into Phase 3: • vibostolimab+pembrolizumab (TIGIT) • quavonlimab+pembrolizumab (CTLA-4) • favezelimab+pembrolizumab (LAG3) • Presented new data for MK-0616 (oral PCSK9) • Advanced pipeline assets MK-2060 (Factor XI inhibitor), MK-5475 (inhaled SGC) and Verquvo • Advanced molnupiravir in post-exposure prophylaxis for COVID-19 • Acquired new assets through business development, including MK-6194 (IL-2 mutein) and sotatercept (ligand trap) • Announced topline results from Phase 3 trials for VAXNEUVANCE (i.e.: PNEU-PED) 30 Approvals 20 NDAs and sBLAs filed In US, EU, Japan and China in 2021, more than: 1.Reflects new approvals and conversions to full approvals 2. Received European Commission approval for KN-564 in January 2022 3. Received Ministry of Health, Labor and Welfare approval in January 2022 -- 25 of 38 -- Molnupiravir represents an important treatment option against COVID-19 in high-risk, non-hospitalized patients 26 • Pandemic continues to impact communities and health care systems • Accessible therapeutic options are needed for high-risk patients • Six independent preclinical studies demonstrated molnupiravir showed activity against Omicron variant in vitro • Molnupiravir is well-positioned to play a role due to its key attributes: – Oral treatment option – Reduction in hospitalizations or deaths in MOVe-OUT trial, including ~90% fewer deaths – Low propensity for drug-drug interactions – Activity against Omicron in vitro – High barrier to resistance Early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19. This study has demonstrated that molnupiravir … potently inhibited the infection of SARS- CoV-2 Omicron variant. -- 26 of 38 -- Continuing to make progress with the broadest early-stage IO clinical development program 27 • Recent approvals in RCC and melanoma ‒ KEYTRUDA is the first and only immunotherapy treatment option in the adjuvant RCC setting ‒ KEYTRUDA is first and only anti-PD1 therapy approved as adjuvant treatment in melanoma across stages IIB, IIC and III disease • Announced findings in NSCLC • Priority review in early-stage, high-risk breast cancer -- 27 of 38 -- Pipeline updates and progress 28 HIV Chronic Cough Cardiometabolic Pneumococcal Disease 1. On clinical hold • Discuss next steps with the FDA for gefapixant • Committed to addressing significant unmet need • Received approval for LYFNUA (gefapixant) in Japan • VAXNEUVANCE approved for adults in U.S. and EU • Under priority review by the FDA in the pediatric setting • Continue to evaluate data in studies with islatravir 1 • Confident in the potential of the NRTTI mechanism for prevention and treatment of HIV • Completed acquisition of Acceleron with ongoing integration • Phase 3 program studying sotatercept for pulmonary arterial hypertension on track -- 28 of 38 -- 34% 24% 23% 13% 6% Extensive research efforts across multiple therapeutic areas and modalities 29 • Become the leading oncology company by 2025 and ensure that position is durable beyond • Extend our impact across cardiometabolic, immunology, infectious diseases, neuroscience and vaccines • Advance internal pipeline and augment with external assets Executing on our strategy to: % of programs per area Programs under other research areas are included within above categories >120 discovery & early development programsOncology Neuroscience ID/Vaccines Immunology Cardiometabolic Disease -- 29 of 38 -- Q&A Rob Davis President & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 30 of 38 -- Appendix 31 -- 31 of 38 -- Q4 2021 continuing operations GAAP financial results summary: 32 Q4 2021 Q4 2020 Change Change Ex-FX Sales $13.5 $10.9 +24% +23% Operating Expenses $5.9 $8.4 -30% -30% Tax Rate 2.2% -2.7% +4.9% N/A GAAP EPS $1.51 ($1.03) +>100% +>100% $ in billions, except EPS amounts -- 32 of 38 -- 2021 continuing operations GAAP financial results summary: 33 2021 2020 Change Change Ex-FX Sales $48.7 $41.5 +17% +16% Operating Expenses $21.9 $22.4 -2% -3% Tax Rate 11.0% 22.9% -11.9pts N/A GAAP EPS $4.86 $1.78 +>100% +>100% $ in billions, except EPS amounts -- 33 of 38 -- 2021 continuing operations non-GAAP financial results summary: Delivered strong revenue and EPS growth 2021 2020 Change Change Ex-FX Sales $48.7 $41.5 +17% +16% Non-GAAP Gross Margin1 76.1% 76.3% -0.2pts -0.3pts Operating Expenses $19.4 $17.7 +9% +8% Tax Rate 11.2% 15.2% -4.0pts N/A Non-GAAP EPS that excludes certain items 1 $6.02 $4.53 +33% +32% $ in billions, except EPS amounts 34 1. Merck is providing certain 2021 and 2020 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results and permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. -- 34 of 38 -- 2021: key pillars driving strong growth over the past four years1 1. All growth rates exclude the impact of foreign exchange 2. In millions 35 2018 2019 2020 2021 $11,084 KEYTRUDA Performance 2018 2019 2020 2021 Lynparza Performance 2018 2019 2020 2021 Lenvima Performance 2018 2019 2020 2021 Animal Health Performance 2018 2019 2020 2021 GARDASIL Performance 2018 2019 2020 2021 BRIDION Performance $7,171 $14,380 $17,186 $187 $725 $444 $149 $404 $580 $4,703 $4,393 $4,212 $5,568 $3,151 $3,737 $3,938 $5,673 $1,131 $1,198 $917 $1,532 $704 +16% YOY +39% YOY +27% YOY +20% YOY +35% YOY +18% YOY $989 -- 35 of 38 -- $8.9 $4.5 $6.6 $14.0 $0.8 $0 $3 $6 $9 $12 $15 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 20B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.72 $1.76 $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022E Dollars per share +11% +2% +2% +2% +2% +2% +11% +15% +7% Order of priority Over the past 12 months Capital investments 2021 to 2025 Commitment to the dividend 36 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% -- 36 of 38 -- Driving value for patients and shareholders by progressing our pipeline 37 Key regulatory milestones since the last earnings call: Key data and presentations since the last earnings call: • In the U.S., received approval for KEYTRUDA as adjuvant therapy for certain patients with RCC based on KN-564 and as adjuvant treatment for patients with stage IIB and IIC melanoma based on KN-716 • Received FDA Emergency Use Authorization for molnupiravir as well as authorization in other markets • FDA granted priority review for VAXNEUVANCE in the pediatric setting and for Lynparza in certain early-stage breast cancers based on OlympiA • In the EU, received approvals for KEYTRUDA in adjuvant RCC based on KN-564, for KEYTRUDA+lenvatinib1 in advanced RCC based on KN-581 and in endometrial cancer based on KN-775, as well as for VAXNEUVANCE in adults • In Japan, received approvals for KEYTRUDA in esophageal cancer based on KN-590 and endometrial cancer based on KN-775 as well as gefapixant • Presented data for KEYTRUDA at SMR, SITC and ASCO GI, for MK-2140 (ROR1-ADC) at ASH, for molnupiravir at ASTMH, and for MK-0616 (oral PCSK9 inhibitor) at AHA • Initiated Phase 3 trial studying Verquvo in patients with chronic heart failure and reduced ejection fraction who have not had a recent worsening heart failure event • Announced topline results for KEYTRUDA as adjuvant treatment for patients with NSCLC based on KN-091 Brand name in Europe is KYSPLIX for RCC and LENVIMA for endometrial 1. -- 37 of 38 -- Phase 2 Phase 3 Under regulatory review Oncology V116 Pneumococcal, adult V184 Chikungunya Virus Vaccines Infectious diseases MK-8189 Schizophrenia Neuroscience Gefapixant (MK-7264) Cough (US, EU) CUBICIN (MK-3009) cSST & Sepsis, pediatric (JPN) General medicine General medicine As of February 2, 2022 V114 Pneumoconjugate Vaccine, adult (JPN), pediatric (US) Vaccines Infectious diseases Oncology Oncology MK-7075 Overgrowth Syndrome MK-1942 Treatment Resistant Depression MK-3655 NASH MK-6024 NASH MK-8591B (islatravir/MK-8507)1 HIV-1 Infection MK-8591D (islatravir/lenacapavir)1 HIV-1 Infection KEYTRUDA (MK-3475) Biliary Tract cSCC (EU) Gastric (EU) Hepatocellular (EU) Mesothelioma Ovarian Prostate SCLC MK-1308A RCC MK-7684A NSCLC MK-4280A CRC LENVIMA (MK-7902) HNSCC Melanoma CRC Esophageal NSCLC Gastric LYNPARZA (MK-7339) NSCLC SCLC CRC WELIREG (MK-6482) RCC TUKYSA (MK-7119) Breast MK-3475 subcutaneous NSCLC MK-8591A (doravirine/islatravir)1 HIV-1 Infection Islatravir (MK-8591)1 HIV-1 prevention KEYTRUDA (MK-3475) MSI-H or dMMR Endometrial (US) TMB-H (JPN) Adjuvant RCC (JPN) Melanoma (EU) High-risk early stage TNBC (EU, JPN) Cervical (EU, JPN) LENVIMA (MK-7902) 1L HCC (US) Advanced unresectable RCC (JPN) LYNPARZA (MK-7339) Prostate cancer (EU) Adjuvant breast cancer (US, EU) MK-5475 Pulmonary Arterial Hypertension MK-2060 Cardiovascular Cardiovascular KEYTRUDA (MK-3475) Advanced Solid Tumors LYNPARZA (MK-7339) Advanced Solid Tumors MK-6440 (ladiratuzumab vedotin) Breast NSCLC SCLC HNSCC Esophageal Gastric Prostate Melanoma MK-1026 Hematological Malignancies V937 Melanoma Breast CSCC HNSCC Solid Tumors MK-4280A (favezelimab/pembrolizumab) RCC SCLC WELIREG (MK-6482) Rare Cancers CRC Pancreatic Biliary HCC Certain VHL tumors (EU) MK-4280 (favezelimab) NSCLC Hematological Malignancies LENVIMA (MK-7902) Biliary Tract Glioblastoma Prostate SCLC Pancreas MK-7684A (vibostolimab/pembrolizumab) Biliary Cervical Esophageal Breast HNSCC HCC Endometrial Prostate Hematological Malignancies MK-1308A (quavonlimab/ pembrolizumab) Advanced Solid Tumors HCC CRC SCLC Melanoma TUKYSA (MK-7119) Advanced Solid Tumors Colorectal Gastric Endometrial NSCLC Bladder Biliary Cervical MK-2140 Breast NSCLC Heme MK-4830 NSCLC SCLC RCC MK-0482 NSCLC MK-1308 NSCLC MK-5890 NSCLC SCLC MK-7684 Melanoma Broad and innovative pipeline to solve significant unmet medical needs 38 Vaccines MK-1654 Respiratory Syncytial Virus 1. On clinical hold Sotatercept (MK-7962) Pulmonary Arterial Hypertension Cardiovascular -- 38 of 38 --